Literature DB >> 8804027

Factors inducing mast cell accumulation in skeletal muscle.

J P Lefaucheur1, B Gjata, A Sebille.   

Abstract

It has been suggested that mast cells contribute to the phenotype of dystrophinopathies, but the mechanisms of their recruitment into the skeletal muscle remain hypothetical. The aim of this study is to quantify the presence of mast cells in muscle during the cellular events of myofibre degeneration and regeneration. For this purpose, we compare the mast cell profile in dystrophin-deficient mdx mice in which muscles exhibit spontaneous cycles of degeneration-regeneration from 3 weeks of age, with that in Swiss mice in which muscles were injured either by ischaemia or by notexin injection. Notexin is an A2-type phospholipase that rapidly disrupts myofibre plasma membranes, while ischaemia results in a slower process of degeneration. Both lesions are followed by a successful regeneration. In intact muscles, mast cell counts (mean +/- SEM/mm2) range from 1.8 +/- 1 to 4.3 +/- 1.6. The injection of notexin is far more potent in recruiting mast cells into damaged muscle than is ischaemia (118.5 +/- 13.0 vs 12.3 +/- 1.8/mm2). Thus we conclude that the early disruption of the myofibre membrane could elicit mast cell accumulation in skeletal muscle. This may explain the elevated number of mast cells observed in mdx muscles, as dystrophin deficiency is though to induce myofibre membrane leakage. On the other hand, mast cells are more numerous in muscles of young and adult mdx mice that are allowed to regenerate, than in muscles of older animals in which there is little regeneration and fibrosis develops. In injured muscles, the peak of mast cell number is at the onset of regeneration (by day 3 after notexin injection, and by day 11 after ischaemia), rather than during the phase of myofibre necrosis. Therefore, we suggest that the mast cells, through the effects of released mediators, could contribute to muscle regeneration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804027

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  7 in total

1.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Authors:  Sheela Shrestha; Barry Wershil; John F Sarwark; Timothy B Niewold; Teresa Philipp; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-09

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

4.  Nociceptive aspects of fibromyalgia.

Authors:  A A Larson; K J Kovács
Journal:  Curr Pain Headache Rep       Date:  2001-08

5.  Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.

Authors:  Emiliano Trias; Sofía Ibarburu; Romina Barreto-Núñez; Valentina Varela; Ivan C Moura; Patrice Dubreuil; Olivier Hermine; Joseph S Beckman; Luis Barbeito
Journal:  JCI Insight       Date:  2017-10-19

Review 6.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

7.  Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis.

Authors:  Ayuka Murakami; Seiya Noda; Tomoyuki Kazuta; Satoko Hirano; Seigo Kimura; Hirotaka Nakanishi; Koji Matsuo; Koyo Tsujikawa; Madoka Iida; Haruki Koike; Kazuma Sakamoto; Yuichiro Hara; Satoshi Kuru; Kenji Kadomatsu; Teppei Shimamura; Tomoo Ogi; Masahisa Katsuno
Journal:  Ann Clin Transl Neurol       Date:  2022-09-15       Impact factor: 5.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.